Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy

ZHOU Ting; PENG Xueyao; ZHAN Xia; BAO Hongrong

doi:10.6039/j.issn.1001-0408.2024.19.15

您当前的位置：

首页 >

文章列表页 >

Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy

更新时间：2024-10-11

- Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy
- ZHONGGUO YAOFANG Vol. 35, Issue 19, Pages: 2411-2415(2024)
- 作者机构：
  
  杭州市临安区第一人民医院药剂科，杭州　311300
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.19.15
  CLC： R977.1+2;R969.3
- Published：15 October 2024，
  
  Received：25 May 2024，
  
  Revised：21 August 2024，
- 稿件说明：
移动端阅览
周婷,彭雪瑶,詹侠等.绝经激素治疗中断的原因调查及影响因素分析 ^Δ[J].中国药房,2024,35(19):2411-2415.

ZHOU Ting,PENG Xueyao,ZHAN Xia,et al.Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy[J].ZHONGGUO YAOFANG,2024,35(19):2411-2415.
周婷,彭雪瑶,詹侠等.绝经激素治疗中断的原因调查及影响因素分析 ^Δ[J].中国药房,2024,35(19):2411-2415. DOI： 10.6039/j.issn.1001-0408.2024.19.15.

ZHOU Ting,PENG Xueyao,ZHAN Xia,et al.Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy[J].ZHONGGUO YAOFANG,2024,35(19):2411-2415. DOI： 10.6039/j.issn.1001-0408.2024.19.15.

摘要

目的

调查更年期综合征患者中断绝经激素治疗的原因，并分析可能导致治疗中断的影响因素。

方法

回顾性选择2022年3月－2023年11月在我院更年期医药联合门诊就诊并建立更年期保健手册的患者，通过手册登记的病史资料和门诊病历系统收集其病例资料。电话随访已接受绝经激素治疗的患者，了解其是否在用药并统计治疗中断的原因。采用单因素分析和多因素Logistic回归分析评价更年期综合征患者中断绝经激素治疗的影响因素。

结果

纳入183例使用绝经激素治疗的患者，根据其是否中断治疗分为中断组（78例）和继续治疗组（105例）。电话随访结果显示，中断的原因主要有自觉无效（16.67%）、担心用药风险（15.38%）、存在慎用情况（12.82%）及发生不良反应（10.26%）。单因素分析结果显示，两组患者的职业、有无并发症、用药方案和骨质、血黏度是否正常比较，差异均有统计学意义（

＜0.05）。多因素Logistic回归分析结果显示，无并发症、骨质减少及疏松、事业单位工作及退休、使用连续序贯用药方案使患者倾向选择继续进行绝经激素治疗（

＜0.05）。

结论

绝经激素治疗中断率较高，自觉无效、担心用药风险、存在慎用情况和发生不良反应对患者影响较大。存在并发症会导致患者中断绝经激素治疗，而骨质减少及疏松、事业单位工作及退休、使用连续序贯用药方案的患者则更倾向于选择继续进行绝经激素治疗。

Abstract

OBJECTIVE

To investigate the reasons for interrupting menopausal hormone therapy in patients with menopausal syndrome and analyze the influencing factors that may lead to treatment interruption.

METHODS

The patients who visited our menopause medicine clinic from March 2022 to November 2023 and established a menopausal health manual were collected retrospectively. The case data were collected through the medical history registered in the manual and the outpatient medical record system. Telephone follow-up was conducted among the patients who had received menopausal hormone therapy to know about whether they were taking medication and to record the reasons for treatment interruption. Univariate analysis and multivariate Logistic regression analysis were adopted to investigate the influencing factors of discontinuing menopausal hormone therapy in patients with menopausal syndrome.

RESULTS

A total of 183 patients receiving menopause hormone therapy were enrolled. They were divided into interruption group （78 cases） and continuation group （105 cases） according to whether the treatment was interrupted. The results of telephone follow-up showed that the reasons in turn for interruption were perceiving ineffectiveness（16.67%）， concerning about medication risk（15.38%）， the existence of caution case（12.82%） and adverse reactions（10.26%）. The results of univariate analysis showed that there were statistically significant differences in occupation， complications， medication regimen， bone condition and blood viscosity between the two groups （

＜0.05）. Multivariate Logistic regression analysis showed that the absence of complications， osteopenia and osteoporosis， working in public institution and retirement， and the continuous sequential medication regimen favored continuation of menopausal hormone therapy （

＜0.05）.

CONCLUSIONS

The interruption rate of menopausal hormone therapy is relatively high， and patients are greatly affected by perceiving ineffectiveness and concerning about medication risks， the existence of caution case， and adverse reactions. Complications can cause patients to interrupt treatment， while factors such as osteopenia and osteoporosis， working in public institutions and retirement， and continuous sequential medication regimens make patients more inclined to choose to continue menopausal hormone therapy.

关键词

更年期综合征绝经激素治疗治疗中断影响因素

Keywords

menopausal hormone therapyinterruption of treatmentinfluencing factors

references

徐丛剑，华克勤.实用妇产科学[M]. 4版.北京：人民卫生出版社，2018：524.

XU C J，HUA K Q. Practice of obstetrics and gynecology[M].4th edition. Beijing：People’s Medical Publishing House，2018：524.

DU L，XU B，HUANG C，et al. Menopausal symptoms and perimenopausal healthcare-seeking behavior in women aged 40-60 years：a community-based cross-sectional survey in Shanghai，China[J]. Int J Environ Res Public Health，2020，17（8）：2640.

谢幸，孔北华，段涛. 妇产科学[M]. 9版. 北京：人民卫生出版社，2018：355.

XIE X，KONG B H，DUAN T.Obstetrics and gynecology[M]. 9th edition. Beijing：People’s Medical Publishing House，2018：355.

中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志，2023，58（1）：4-21.

Menopausal Study Group，Obstetrics and Gynecology Branch，Chinese Medical Association.The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines[J]. Chin J Obstet Gynecol，2023，58（1）：4-21.

孔令伶俐，常青，丁岩，等.基层医院更年期妇女健康分级管理流程建议：2023[J/OL].中华妇幼临床医学杂志（电子版），2023，19（6）：621-628[2024-05-23]. https：//zhfylcyxzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1673-5250.2023.06.001.DOI：10.3877/cma.j.issn.1673-5250.2023.06.001https://zhfylcyxzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1673-5250.2023.06.001.DOI:10.3877/cma.j.issn.1673-5250.2023.06.001.

KONG L L L，CHANG Q，DING Y，et al. Tiered medical process for health management of climacteric women in primary medical institutions：2023[J/OL].Chin J Obstet Gynecol Pediatr （Electron Ed），2023，19（6）：621-628[2024-05-23]. https：//zhfylcyxzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1673-5250.2023.06.001.DOI：10.3877/cma.j.issn.1673-5250.2023.06.001https://zhfylcyxzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1673-5250.2023.06.001.DOI:10.3877/cma.j.issn.1673-5250.2023.06.001.

WANG R X，WANG Y，FANG L Y，et al. Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors：a systematic review and meta-analysis[J]. BMC Cancer，2024，24（1）：42.

WANG Y P，YU Q. The treatment of menopausal symptoms by traditional Chinese medicine in Asian countries[J]. Climacteric，2021，24（1）：64-67.

韩芳，韩丽，寿坚. 健康管理策略对绝经过渡期女性绝经相关症状临床干预效果研究[J]. 中国预防医学杂志，2020，21（7）：798-802.

HAN F，HAN L，SHOU J. Effect of long-term health management strategy on menopausal related symptoms and quality of life of women with perimenopause[J]. Chin Prev Med，2020，21（7）：798-802.

SHOBEIRI F，JENABI E，KHATIBAN M，et al. The effect of educational program on quality of life in menopausal women：a clinical trial[J]. J Menopausal Med，2017，23（2）：91-95.

RATHNAYAKE N，ALWIS G，LENORA J，et al. Effect of health-promoting lifestyle modification education on knowledge，attitude，and quality of life of postmenopausal women[J]. Biomed Res Int，2020，2020：3572903.

周婷，鲍红荣，詹侠，等. 临床药师参与1例绝经综合征伴子宫肌瘤、血压血脂异常的治疗实践[J]. 中国临床药学杂志，2023，32（6）：462-466.

ZHOU T，BAO H R，ZHAN X，et al. Clinical pharmacists participated in the treatment of a patient of menopausal syndrome with uterine fibroids and abnormal blood pressure and lipid levels[J]. Chin J Clin Pharm，2023，32（6）：462-466.

SOBEL T H，SHEN W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events：a scoping review[J]. Menopause，2022，29（4）：483-490.

GRAMLING R，EATON C B，ROTHMAN K J，et al. Hormone replacement therapy，family history，and breast cancer risk among postmenopausal women[J]. Epidemiology，2009，20（5）：752-756.

李长滨，金凤，陶敏芳，等. （围）绝经期综合征患者激素替代治疗依从性及其影响因素分析[J]. 山东医药，2014，54（18）：49-50.

LI C B，JIN F，TAO M F，et al. Compliance and influen- cing factors of hormone replacement therapy in patients with （peri）menopausal syndrome[J]. Shandong Med J，2014，54（18）：49-50.

PRENTICE R L，ARAGAKI A K，CHLEBOWSKI R T，et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age[J]. Am J Epidemiol，2021，190（3）：365-375.

IORGA A，CUNNINGHAM C M，MOAZENI S，et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy[J]. Biol Sex Differ，2017，8（1）：33.

NAFTOLIN F，FRIEDENTHAL J，NACHTIGALL R， et al. Cardiovascular health and the menopausal woman：the role of estrogen and when to begin and end hormone treatment[J]. F1000Res，2019，8：F1000FacultyRev-F1000Faculty1576.

NEWSON L. Menopause and cardiovascular disease[J]. Post Reprod Health，2018，24（1）：44-49.

中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华预防医学杂志，2019，53（1）：13-35.

The Joint Task Force for Guideline on the Assessment and Management of Cardiovascular Risk in China.Guideline on the assessment and management of cardiovascular risk in China[J]. Chin J Prev Med，2019，53（1）：13-35.

PASCHOU S A，ATHANASIADOU K I，PAPANAS N. Menopausal hormone therapy in women with type 2 diabetes mellitus：an updated review[J]. Diabetes Ther，2024，15（4）：741-748.

KAPOOR E，KLING J M，LOBO A S，et al. Menopausal hormone therapy in women with medical conditions[J]. Best Pract Res Clin Endocrinol Metab，2021，35（6）：101578.

冯巍，史惠蓉，贾艳艳. 激素治疗绝经综合征早期患者的依从性及其影响因素分析[J]. 中华老年医学杂志，2016，35（7）：732-735.

FENG W，SHI H R，JIA Y Y. Compliance and its influen- cing factors to hormone replacement therapy in patients with early menopausal syndrome[J]. Chin J Geriatr，2016，35（7）：732-735.

董慧敏，黄俊松，苟芬，等. 围绝经期女性绝经激素治疗依从性研究进展[J]. 中外医学研究，2023，21（11）：169-173.

DONG H M，HUANG J S，GOU F，et al. Research pro- gress on compliance of menopausal hormone therapy in perimenopausal women[J]. Chin Foreign Med Res，2023，21（11）：169-173.

中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南：2022[J]. 中华骨质疏松和骨矿盐疾病杂志，2022，15（6）：573-611.

Osteoporosis and Bone Mineral Salt Disease Branch， Chinese Medical Association.Guidelines for diagnosis and treatment of primary osteoporosis：2022[J]. Chin J Osteoporos Bone Miner Res，2022，15（6）：573-611.

DE VILLIERS T J. Bone health and menopause：osteoporosis prevention and treatment[J]. Best Pract Res Clin Endocrinol Metab，2024，38（1）：101782.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement

The characteristics and influencing factors of medicine cost for orthopedic surgery patients in hospitals of Shanxi province

Analysis of DRG grouping effect and influential factors of hospitalization cost of diabetic patients

Analysis of the burden of polypharmacy and its influencing factors among elderly tuberculosis patients in Guizhou province

Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia

Related Author

LIU Yuxin

WEN Xiaotong

DUAN Fengran

WANG Yue

YANG Ying

MAO Zongfu

LI Weipeng

SHANG Nan

Related Institution

Dong Fureng Institution of Economic and Social Development， Wuhan University

Global Health Institute， Wuhan University

School of Public Health， Wuhan University

School of Nursing， Tongji Medical College of Huazhong University of Science and Technology

School of Pharmacy， Shanxi Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰